Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 5Carboplatin 4X-Rays 3Rituximab 3Prednisone 3Nivolumab 3Magnetic Resonance Spectroscopy 3Abiraterone Acetate 3trastuzumab deruxtecan 2talquetamab 2pertuzumab 2pembrolizumab 2olaparib 2niraparib 2erdafitinib 2durvalumab 2belzutifan 2apalutamide 2acalabrutinib 2Trastuzumab 2Sunitinib 2Phantoms, Imaging 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Dexamethasone 2Dasatinib 2Cyclophosphamide 2Crizotinib 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × cabozantinib × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡